Pituitary thyrotropin-releasing hormone receptors: local anesthetic effects on binding and responses.
Pharmacological agents are widely used to probe the mechanism of action of TRH. A number of these drugs behave as local anesthetics at high concentrations. The effect of local anesthetics on the binding of [3H]Me-TRH to specific receptors was studied using the GH4C1 line of rat pituitary tumor cells. [3H]Me-TRH binding was inhibited by classical local anesthetics with the order of potency (IC50 values): dibucaine (0.37 mM) greater than tetracaine (1.2 mM) greater than lidocaine (3.3 mM) greater than procaine and benzocaine (greater than 10 mM). IC50 values for other drugs with local anesthetic properties that inhibited [3H]Me-TRH were: 100 microM trifluoperazine, 100 microM imipramine, 170 microM chlorpromazine, 300 microM verapamil, and 700 microM propranolol. Inhibition by tetracaine and verapamil increased as the pH was raised from 6 to 8.5, indicating that the free base form of the amine drugs was the inhibitory species, and the local anesthetic effect was greater at 37 C than at 24 C or 0 C. [3H]Me-TRH binding to receptors in isolated membranes was inhibited to the same extent as binding to receptors on intact cells. Local anesthetics were 3- to 20-fold less potent at inhibiting [3H]Me-TRH to digitonin-solubilized receptors than binding to intact cells. In contrast, the potency of chlordiazepoxide, a putative TRH antagonist, to inhibit [3H]Me-TRH binding was equal using cells and solubilized receptors (IC50 = 10 microM). Local anesthetics inhibited TRH-stimulated PRL release and also inhibited basal PRL secretion and secretion stimulated by two nonhormonal secretagogues, (Bu)2cAMP and a phorbol ester.(ABSTRACT TRUNCATED AT 250 WORDS)
Phillips
W J
WJ
Department of Pharmacology, University of Rochester School of Medicine and Dentistry, New York 14642.
Enyeart
J J
JJ
Hinkle
P M
PM
D000779:Anesthetics, Local / Q000494:pharmacology*; D000818:Animals; D001566:Benzocaine / Q000494:pharmacology; D002707:Chlordiazepoxide / Q000493:pharmacokinetics; D002746:Chlorpromazine / Q000494:pharmacology; D003992:Dibucaine / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D007099:Imipramine / Q000493:pharmacokinetics; D008012:Lidocaine / Q000494:pharmacology; D010902:Pituitary Gland / Q000378:metabolism*; D011343:Procaine / Q000494:pharmacology; D011388:Prolactin / Q000378:metabolism; D011433:Propranolol / Q000493:pharmacokinetics; D051381:Rats; D017981:Receptors, Neurotransmitter / Q000187:drug effects* / Q000378:metabolism; D018025:Receptors, Thyrotropin-Releasing Hormone; D013748:Tetracaine / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism* / Q000502:physiology; D014268:Trifluoperazine / Q000493:pharmacokinetics; D014700:Verapamil / Q000493:pharmacokinetics
D000779:Anesthetics, Local; D017981:Receptors, Neurotransmitter; D018025:Receptors, Thyrotropin-Releasing Hormone; D013748:Tetracaine; D014268:Trifluoperazine; D011343:Procaine; D013973:Thyrotropin-Releasing Hormone; D002707:Chlordiazepoxide; D011388:Prolactin; D008012:Lidocaine; D011433:Propranolol; D014700:Verapamil; D003992:Dibucaine; D007099:Imipramine; D001566:Benzocaine; D002746:Chlorpromazine